Ocugen Nears Regulatory Milestone with Key Gene Therapy Trial

Biotechnology firm Ocugen has completed patient enrollment for the pivotal Phase 3 clinical trial of its lead candidate, OCU400, a gene therapy designed to treat Retinitis pigmentosa. This achievement marks a significant transition from clinical development to the regulatory submission phase for the company. Topline data from this study is anticipated in the first quarter of 2027.

Regulatory Pathway and Pipeline Progress

The company’s regulatory strategy is now taking shape. Management intends to initiate a rolling Biologics License Application (BLA) submission with the U.S. Food and Drug Administration (FDA) starting in the third quarter of 2026. Successful development could position OCU400 as Ocugen’s first commercially approved product.

Progress is also evident elsewhere in the pipeline. Preliminary 12-month data from a Phase 2 study for OCU410, targeting geographic atrophy, demonstrated a 46% reduction in lesion growth compared to the control group. For OCU410ST, a therapy for Stargardt disease, data from a Phase 2/3 trial is expected in the second quarter of 2027.

Financial Position and Corporate Developments

Ocugen’s financial results reflect the costs of its advancing clinical programs. The company reported a net loss of $0.06 per share for the fourth quarter of 2025. For the full year, research and development expenses totaled $39.8 million, contributing to an annual net loss of $0.23 per share.

Should investors sell immediately? Or is it worth buying Ocugen?

As of December 31, 2025, Ocugen held $18.9 million in cash and equivalents. A capital raise finalized in January 2026 has strengthened its liquidity position. Current resources are projected to fund operations into the fourth quarter of 2026, with the potential exercise of existing warrants possibly extending this financial runway.

A separate corporate matter is proceeding in court. The company has filed a petition with the Delaware Court of Chancery to confirm a shareholder-approved increase in authorized common stock from 295 million to 390 million shares. A hearing on this matter is scheduled for May 2026.

A Period of Anticipated Catalysts

The coming quarters present several potential catalysts for Ocugen. The commencement of the rolling BLA submission in Q3 2026 will be a key event, formally initiating the regulatory review process for OCU400. Subsequently, the Phase 3 data readout in early 2027 will be critical, revealing whether the therapy meets its primary efficacy and safety endpoints.